uniQure Announces Presentations at the Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)
19 oct. 2021 07h05 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Oct. 19, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Presents New Preclinical Data in SCA3, Fabry Disease, and Hemophilia A at the ASGCT Annual Meeting
14 mai 2020 07h00 HE
|
uniQure Inc.
~ Substantial Presence with 22 Data Presentations Highlighting Breadth of Research, Technology and Manufacturing Platform ~ ~ New Non-Human Primate Data Demonstrate Feasibility of...
uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)
15 avr. 2019 12h15 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 15, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Highlights Pipeline Expansion and Advancements in Technology at Research & Development Day
19 nov. 2018 12h15 HE
|
uniQure Inc.
~ Unveils New AAV Gene Therapy Approaches to Hemophilia A, Fabry Disease and Spinocerebellar Ataxia Type 3 ~ ~ Introduces miQURE™ Gene Silencing Platform with Applications Across Multiple Indications...
Reaching underserved patients in the kidney community: American Kidney Fund expands online resources for rare diseases
06 sept. 2018 11h30 HE
|
American Kidney Fund
ROCKVILLE, Md., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Because many relatively unknown rare diseases can cause permanent damage to the kidneys, the American Kidney Fund (AKF) today announced it has...
Protalix BioTherapeutics to Hold Full-Year 2016 Financial Results and Corporate Update Conference Call on March 16, 2017
09 mars 2017 07h30 HE
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, March 09, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...
Protalix BioTherapeutics Announces Additional Positive Data from its Phase I/II Clinical Trial for PRX-102 for the Treatment of Fabry Disease
10 août 2016 07h30 HE
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today additional positive data from its phase I/II clinical trial of...
Protalix BioTherapeutics to Present at the Jefferies 2016 Global Healthcare Conference
02 juin 2016 07h30 HE
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, June 02, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), today announced that Moshe Manor, the Company's President and Chief Executive...